NEW! Introducing SUREmAb™
An Expedited, Cost-Efficient Solution for Monoclonal Antibodies (mAbs)
Built on the SUREtechnology Platform, SUREmAb shortens development and manufacturing for mAbs. It enables RCB development in as little as 9 weeks and drug substance release in 11 months.
Specific
Precision-engineered for a broad range of molecules
Unique
Proprietary platform technologies cover 210+ patents
Robust
Rapid, reliable, and versatile for producing recombinant proteins
Efficient
Streamlined and timely from early-stage to GMP manufacturing
Expect versatility and leading performance with our SURE CHO-M Cell Line™
Our proprietary SURE CHO-M Cell Line is a game-changer in biologics production. Derived from CHO-K1 cells, this high-performing cell line was specifically developed to overcome protein expression bottlenecks. It enables the expression of a diverse range of molecules with high titers, ensuring versatility, high performance, and stability over 60 generations.
Robust verification with genomic characterization and monoclonality assessment
In ensuring the safety and success of biotherapeutics, we perform extensive genomic characterization and monoclonality assessment, based on the fuly sequencing of our proprietary SURE CHO-M Cell Line™. Leveraging next-generation sequencing technologies such as Illumina sequencing, we provide the detailed genomic data that is crucial for cost-effective biomanufacturing, safe clinical trials, and overall program success. Our in house genomic analysis technologies and proprietary SUREsignature™ services deliver comprehensive monoclonality assessments, and genomic characterization of your RCBs, providing the right level of assurance and detailed support for your regulatory filings.
Learn More about Genomic Analysis Services
Extensive, Diverse Molecule Support
Across a wide range of molecules, including mAbs, bispecifics, Fc fusions, and more
At KBI Biopharma, our SUREtechnology Platform has successfully supported the expression of a wide range of molecules for biopharmaceutical and vaccine development, coupled with robust verification to assure biosafety and efficacy. Across 300+ programs for 200+ global customers, we have supported the development of:
- 150+ monoclonal antibodies (mAbs)
- 40+ bispecific antibodies
- 35+ Fc fusions
- 40+ non-IgG molecules, including vaccines, blood factors, hormones, and enzymes, among others
Not just another CLD platform
Our unique and patented technology enables faster, safer, and more efficient biopharmaceutical development.
Embedded in our transfection vectors are patented chromatin modifiers that unwind the DNA at the site of transgene integration, boosting transcription and therefore increasing recombinant protein expression. These epigenetic elements are key to obtaining the highest - and most reproducible - gene expression levels across protein types.
Furthermore, we believe in full transparency and robust verification. To that end, our extensive genomic characterization and monoclonality assessment services assure the biosafety and efficacy of developed products.
